Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Gene |
RCV000188539 | SCV000242157 | benign | not specified | 2014-11-21 | criteria provided, single submitter | clinical testing | This variant is considered likely benign or benign based on one or more of the following criteria: it is a conservative change, it occurs at a poorly conserved position in the protein, it is predicted to be benign by multiple in silico algorithms, and/or has population frequency not consistent with disease. |
Eurofins Ntd Llc |
RCV000726207 | SCV000342910 | uncertain significance | not provided | 2018-08-22 | criteria provided, single submitter | clinical testing | |
Wong Mito Lab, |
RCV000758388 | SCV000887064 | likely benign | Progressive sclerosing poliodystrophy | 2018-10-01 | criteria provided, single submitter | clinical testing | The NM_002693.2:c.3652C>T (NP_002684.1:p.Leu1218=) [GRCH38: NC_000015.10:g.89316819G>A] variant in FANCI gene is interpretated to be a Likely Benign based on ACMG guidelines (PMID: 25741868). This variant meets the following evidence codes reported in the ACMG-guideline. BP4:Computational evidence/predictors indicate no impact on the FANCI structure, function, or protein-protein interaction. BP7:The variant is silent with non predicted splice impact. Based on the evidence criteria codes applied, the variant is suggested to be Likely Benign. |
Labcorp Genetics |
RCV000758388 | SCV001006714 | likely benign | Progressive sclerosing poliodystrophy | 2024-01-11 | criteria provided, single submitter | clinical testing | |
Prevention |
RCV003985749 | SCV004785845 | likely benign | POLG-related disorder | 2023-01-24 | no assertion criteria provided | clinical testing | This variant is classified as likely benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). |